Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy Markus SchwaigerChristian Peschel OriginalPaper 16 May 2006 Pages: 1 - 5
Imaging biomarkers as surrogate endpoints for drug development Wolf S. Richter ReviewPaper 24 May 2006 Pages: 6 - 10
Current standards for response evaluation by imaging techniques S. J. Gwyther 17 June 2006 Pages: 11 - 15
How should we analyse FDG PET studies for monitoring tumour response? Adriaan A. LammertsmaCorneline J. HoekstraOtto S. Hoekstra 09 June 2006 Pages: 16 - 21
Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas N. George Mikhaeel ReviewPaper 09 June 2006 Pages: 22 - 26
Monitoring chemotherapy and radiotherapy of solid tumors Wolfgang A. WeberHinrich Wieder ReviewPaper 11 May 2006 Pages: 27 - 37
Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose? Sven N. ReskeSandra Deisenhofer ReviewPaper 24 May 2006 Pages: 38 - 43
Hypoxia imaging-directed radiation treatment planning J.G. RajendranK.R.G. HendricksonD.A. Mankoff Original article 09 June 2006 Pages: 44 - 53
αvβ3-integrin imaging: a new approach to characterise angiogenesis? Roland Haubner Original paper 22 June 2006 Pages: 54 - 63